Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. CNS Pharmaceuticals, Inc. has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as a collaboration and asset purchase agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas. more
Time Frame | CNSP | Sector | S&P500 |
---|---|---|---|
1-Week Return | 0.88% | -2.27% | -0.57% |
1-Month Return | -17.35% | -3.96% | 1.21% |
3-Month Return | -30.57% | -9.7% | 7.57% |
6-Month Return | -97.16% | -3.37% | 11.45% |
1-Year Return | -99.88% | 3.71% | 28.48% |
3-Year Return | -99.99% | 3.8% | 29.52% |
5-Year Return | -100% | 39.78% | 90.66% |
10-Year Return | -100% | 106.91% | 203.75% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 1.96K | 11.10K | 13.07K | 11.76K | 4.13K | [{"date":"2019-12-31","value":14.96,"profit":true},{"date":"2020-12-31","value":84.9,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":89.95,"profit":true},{"date":"2023-12-31","value":31.63,"profit":true}] |
Gross Profit | (1.96K) | (11.10K) | (13.07K) | (11.76K) | (4.13K) | [{"date":"2019-12-31","value":-195500,"profit":false},{"date":"2020-12-31","value":-1109600,"profit":false},{"date":"2021-12-31","value":-1307000,"profit":false},{"date":"2022-12-31","value":-1175600,"profit":false},{"date":"2023-12-31","value":-413400,"profit":false}] |
Gross Margin | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 3.83M | 9.45M | 14.03M | 15.27M | 18.87M | [{"date":"2019-12-31","value":20.32,"profit":true},{"date":"2020-12-31","value":50.12,"profit":true},{"date":"2021-12-31","value":74.36,"profit":true},{"date":"2022-12-31","value":80.93,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (3.83M) | (9.45M) | (14.03M) | (15.27M) | (18.87M) | [{"date":"2019-12-31","value":-383297700,"profit":false},{"date":"2020-12-31","value":-945460700,"profit":false},{"date":"2021-12-31","value":-1402729300,"profit":false},{"date":"2022-12-31","value":-1526710700,"profit":false},{"date":"2023-12-31","value":-1886510800,"profit":false}] |
Total Non-Operating Income/Expense | (88.47K) | (6.53K) | (18.57K) | (14.05K) | 21.33K | [{"date":"2019-12-31","value":-414.74,"profit":false},{"date":"2020-12-31","value":-30.6,"profit":false},{"date":"2021-12-31","value":-87.06,"profit":false},{"date":"2022-12-31","value":-65.89,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (3.88M) | (9.46M) | (14.04M) | (15.27M) | (18.85M) | [{"date":"2019-12-31","value":-387721100,"profit":false},{"date":"2020-12-31","value":-945787100,"profit":false},{"date":"2021-12-31","value":-1403657800,"profit":false},{"date":"2022-12-31","value":-1527413400,"profit":false},{"date":"2023-12-31","value":-1885122600,"profit":false}] |
Income Taxes | 42.28K | 3.26K | 9.29K | 7.03K | (4.00) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":7.72,"profit":true},{"date":"2021-12-31","value":21.96,"profit":true},{"date":"2022-12-31","value":16.62,"profit":true},{"date":"2023-12-31","value":-0.01,"profit":false}] |
Income After Taxes | (3.92M) | (9.46M) | (14.05M) | (15.28M) | (18.85M) | [{"date":"2019-12-31","value":-391949000,"profit":false},{"date":"2020-12-31","value":-946113500,"profit":false},{"date":"2021-12-31","value":-1404586300,"profit":false},{"date":"2022-12-31","value":-1528116100,"profit":false},{"date":"2023-12-31","value":-1885122200,"profit":false}] |
Income From Continuous Operations | (3.88M) | (9.46M) | (14.04M) | (15.27M) | (18.61M) | [{"date":"2019-12-31","value":-387721100,"profit":false},{"date":"2020-12-31","value":-945787100,"profit":false},{"date":"2021-12-31","value":-1403657800,"profit":false},{"date":"2022-12-31","value":-1527413400,"profit":false},{"date":"2023-12-31","value":-1861282700,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (3.92M) | (9.46M) | (14.50M) | (15.27M) | (18.85M) | [{"date":"2019-12-31","value":-391949000,"profit":false},{"date":"2020-12-31","value":-945787100,"profit":false},{"date":"2021-12-31","value":-1449520000,"profit":false},{"date":"2022-12-31","value":-1527413400,"profit":false},{"date":"2023-12-31","value":-1885122600,"profit":false}] |
EPS (Diluted) | (7.10) | (17.10) | (16.20) | (11.32) | (54.03) | [{"date":"2019-12-31","value":-710,"profit":false},{"date":"2020-12-31","value":-1710,"profit":false},{"date":"2021-12-31","value":-1620,"profit":false},{"date":"2022-12-31","value":-1132.11,"profit":false},{"date":"2023-12-31","value":-5402.89,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
CNSP | |
---|---|
Cash Ratio | 1.72 |
Current Ratio | 1.82 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
CNSP | |
---|---|
ROA (LTM) | -224.00% |
ROE (LTM) | -1018.78% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
CNSP | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.55 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.45 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
CNSP | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 1.84 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | 0.40 |
Cns Pharmaceuticals Inc (CNSP) share price today is $0.1029
Yes, Indians can buy shares of Cns Pharmaceuticals Inc (CNSP) on Vested. To buy Cns Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CNSP stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Cns Pharmaceuticals Inc (CNSP) via the Vested app. You can start investing in Cns Pharmaceuticals Inc (CNSP) with a minimum investment of $1.
You can invest in shares of Cns Pharmaceuticals Inc (CNSP) via Vested in three simple steps:
The 52-week high price of Cns Pharmaceuticals Inc (CNSP) is $89.6. The 52-week low price of Cns Pharmaceuticals Inc (CNSP) is $0.1.
The price-to-earnings (P/E) ratio of Cns Pharmaceuticals Inc (CNSP) is
The price-to-book (P/B) ratio of Cns Pharmaceuticals Inc (CNSP) is 1.84
The dividend yield of Cns Pharmaceuticals Inc (CNSP) is 0.00%
The market capitalization of Cns Pharmaceuticals Inc (CNSP) is $5.28M
The stock symbol (or ticker) of Cns Pharmaceuticals Inc is CNSP